探讨加味知柏汤与α受体阻断剂联合治疗慢性前列腺炎的临床疗效。方法：选取深圳市龙岗中心医院2013年2月—2014年10月收治的慢性前列腺炎患者114例，按随机数字表法分成2组各57例。对照组患者给予α受体阻断剂治疗，观察组患者在此基础上联合加味知柏汤治疗。比较2组患者治疗前、后慢性前列腺炎症状评分（NIH-CPSI）的差异，记录最大尿流率、平均尿流率及肿瘤坏死因子α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）变化情况。结果：观察组患者NIH-CPSI评分由治疗前的（23.7±2.7）分降低为治疗后的（13.4±2.2）分，对照组由治疗前的（23.9±2.6）分降低为治疗后的（16.9±2.4）分，均较同组治疗前明显降低，且观察组降低幅度大于对照组，差异有统计学意义（P＜0.05）。观察患者最大尿流率由治疗前的（15.8±5.5）V／（ml· s）升高为治疗后的（21.0±2.2）V／（ml· s），对照组由治疗前的（15.9±5.3）V／（ml· s）升高为治疗后的（18.9±2.0）V／（ml· s），均较同组治疗前明显降低，且观察组降低幅度大于对照组，差异有统计学意义（P＜0.05）。观察组患者平均尿流率由治疗前的（8.5±3.3）V／（ml· s）升高为治疗后的（12.3±1.9）V／（ml· s），对照组由治疗前的（8.7±3.1）V／（ml· s）升高为治疗后的（10.5±1.7）V／（ml· s），均较同组治疗前明显降低，且观察组降低幅度大于对照组，差异有统计学意义（P＜0.05）。观察组患者TNF-α、IL-6、IL-8指标由治疗前的（92.7±33.0） pg／ml、（1.7±0.2）μg／ml、（12.6±2.5）μg／ml降低为治疗后的（63.7±15.1） pg／ml、（1.1±0.2）μg／ml、（7.4±1.0）μg／ml，对照组由治疗前的（92.5±33.1） pg／ml、（1.7±0.3）μg／ml、（12.7±2.3）μg／ml降低为治疗后的（79.9±14.7） pg／ml、（1.5±0.2）μg／ml、（9.3±1.3）μg／ml，均较同组治疗前明显降低，且观察组降低幅度大于对照组，差异有统计学意义（ P＜0.05）。结论：加味知柏汤与α受体阻断剂联合治疗慢性前列腺炎疗效确切，可有效缓解其炎症反应、改善患者前列腺功能，值得临床推广。%OBJECTIVE:To investigate the clinical efficacy of modified zhibai decoction combined with α-retardant in treatment of chronic prostatitis .METHODS:114 cases with chronic prostatitis admitted into Shenzhen Longgang Central Hospital from Feb.2013 to Oct.2014 were selected to be divided into two groups via the random number table , with 57 cases in each .The control group were treated with α-retardant therapy , while the observation group additionally received modified zhibai decoction based on the control group .Differences in chronic prostatitis symptom scores (NIH-CPSI) were compared between two groups before and after treatment , changes of maximal urinary flow rate , average urinary flow rate , TNF-α, IL-6 and IL-8 were recorded .RESULTS:After treatment , NIH-CPSI scores in observation group decreased from (23.7 ±2.7) to (13.4 ±2.2), and in control group decreased from (23.9 ±2.6) to (16.9 ±2.4), the data in two groups were significantly lower than those before treatment (P<0.05), the decline in observation group was greater than that in control group , with statistically significant difference ( P <0.05 ) .The maximal urinary flow rate in observation group increased from (15.8 ±5.5) V/(ml· s) to (21.0 ±2.2) V/(ml· s), and in control group, it decreased from (15.9 ±5.3) V/(ml· s) to ( 18.9 ±2.0)V/(ml· s), the data in two groups were significantly lower than those before treatment (P<0.05), the decline in observation group was greater than that in control group , with statistically significant difference ( P<0.05) .The average urinary flow rate in observation group increased from (8.5 ±3.3) V/(ml· s) to (12.3 ±1.9) V/(ml· s), and in control group, it decreased from (8.7 ±3.1) V/(ml· s) to ( 10.5 ±1.7)V/(ml· s), the data in two groups were significantly lower than those before treatment (P<0.05), the decline in observation group was greater than that in control group, with statistically significant difference(P<0.05).TNF-α, IL-6 and IL-8 of observation group all had a significant decrease from (92.7 ±33.0) pg/ml,(1.7 ±0.2) μg/ml and (12.6 ±2.5) μg/m to (63.7 ±15.1) pg/ml,(1.1 ±0.2) μg/ml,(7.4 ±1.0)μg/m;of control group, the data decreased from (92.5 ±33.1) pg/ml, (1.7 ±0.3) μg/ml and (12.7 ±2.3) μg/ml to (79.9 ±14.7) pg/ml,(1.5 ±0.2)μg/ml and (9.3 ±1.3) μg/ml, the decline in observation group was greater than that in control group, with statistically significant difference(P<0.05).CONCLUSIONS:The efficacy of modified zhibai decoction combined with α-retardant therapy in treatment of chronic prostatitis is significantly effective , which can relieve the inflammatory reactions , improve the prostate function of patients and is worthy of the clinical promotion .
展开▼
